- Home
- ITIC vs ALT Comparison
ITIC vs ALT Comparison
Compare ITIC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITIC | ALT |
|---|---|---|
| Founded | 1972 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.1M | 415.3M |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ITIC | ALT |
|---|---|---|
| Price | $227.81 | $4.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 11.1K | ★ 3.6M |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | ★ 43.49 | 19.28 |
| EPS | ★ 14.59 | N/A |
| Revenue | ★ $258,298,000.00 | $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.79 | ★ N/A |
| Revenue Growth | ★ 14.93 | N/A |
| 52 Week Low | $190.20 | $2.91 |
| 52 Week High | $288.98 | $7.73 |
Technical Indicators
Market Signals| Indicator | ITIC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 44.18 |
| Support Level | $194.68 | $3.78 |
| Resistance Level | $235.03 | $4.53 |
| Average True Range (ATR) | 10.98 | 0.21 |
| MACD | -4.05 | -0.04 |
| Stochastic Oscillator | 26.15 | 23.93 |
Price Performance
Historical ComparisonAbout ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.